On January 21, 2025, Revelation announced the commencement of its PRIME (PReconditioning IMmunostimulatory Evaluation) Phase 1b clinical study of escalating doses of intravenously administered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results